| Literature DB >> 30901860 |
Ines Greco1, Johannes E Hansen2, Bimal Jana3, Natalia Molchanova4, Alberto Oddo5, Peter W Thulstrup6, Peter Damborg7, Luca Guardabassi8,9, Paul R Hansen10.
Abstract
Methicillin-resistant Staphylococcus pseudintermedius (MRSP) constitutes an emerging health problem for companion animals in veterinary medicine. Therefore, discovery of novel antimicrobial agents for treatment of Staphylococcus-associated canine infections is urgently needed to reduce use of human antibiotics in veterinary medicine. In the present work, we characterized the antimicrobial activity of the peptoid D2 against S. pseudintermedius and Pseudomonas aeruginosa, which is another common integumentary pathogen in dogs. Furthermore, we performed a structure⁻activity relationship study of D2, which included 19 peptide/peptoid analogs. Our best compound D2D, an all d-peptide analogue, showed potent minimum inhibitory concentrations (MICs) against canine S. pseudintermedius (2⁻4 µg/mL) and P. aeruginosa (4 µg/mL) isolates as well as other selected dog pathogens (2⁻16 µg/mL). Time⁻kill assays demonstrated that D2D was able to inhibit MRSP in 30 min at 1× MIC, significantly faster than D2. Our results suggest that at high concentrations D2D is rapidly lysing the bacterial membrane while D2 is inhibiting macromolecular synthesis. We probed the mechanism of action at sub-MIC concentrations of D2, D2D, the l-peptide analog and its retro analog by a macromolecular biosynthesis assay and fluorescence spectroscopy. Our data suggest that at sub-MIC concentrations D2D is membrane inactive and primarily works by cell wall inhibition, while the other compounds mainly act on the bacterial membrane.Entities:
Keywords: Pseudomonas aeruginosa; antimicrobial; canine infections; methicillin-resistant Staphylococcus pseudintermedius; mode of action; peptide; peptoid
Mesh:
Substances:
Year: 2019 PMID: 30901860 PMCID: PMC6470533 DOI: 10.3390/molecules24061121
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Lead compound D2 and its most active analogue D2D.
Figure 2Time–kill curve of D2 against a clinical MRSP isolate (C22963). GC: Growth control. We observed regrowth after 24 h (data not shown).
Structures, antimicrobial activity (MIC, µg/mL) and hemolytic activity (% at 150 µM) of eight analogues of D2 resulting from Gly-scan.
| ID | SEQUENCE a | MIC | HA f | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MSSP b | MRSP c | SA d | PA e | ||||||||||
|
| Nlys | Nlys | N1Nal | N4MePhe | Nlys | N1Nal | Nlys | NNle | 2–4 | 4 | 8 | 16 | 24 |
|
| Gly | Nlys | N1Nal | N4MePhe | Nlys | N1Nal | Nlys | NNle | 4 | 4 | 16 | 32 | 42 |
|
| Nlys | Gly | N1Nal | N4MePhe | Nlys | N1Nal | Nlys | NNle | 16 | 8 | 16 | 64 | 48 |
|
| Nlys | Nlys | Gly | N4MePhe | Nlys | N1Nal | Nlys | NNle | 64 | 64 | >64 | >64 | 56 |
|
| Nlys | Nlys | N1Nal | Gly | Nlys | N1Nal | Nlys | NNle | 64 | 32 | >64 | >64 | 40 |
|
| Nlys | Nlys | N1Nal | N4MePhe | Gly | N1Nal | Nlys | NNle | 4 | 4 | 32 | 16 | 25 |
|
| Nlys | Nlys | N1Nal | N4MePhe | Nlys | Gly | Nlys | NNle | >64 | >64 | >64 | >64 | 6 |
|
| Nlys | Nlys | N1Nal | N4MePhe | Nlys | N1Nal | Gly | NNle | 8 | 4 | 16 | 16 | 85 |
|
| Nlys | Nlys | N1Nal | N4MePhe | Nlys | N1Nal | Nlys | Gly | 8 | 8 | 32 | 32–64 | 49 |
a Products synthesized as C-terminal amides; b Methicillin sensitive Staphylococcus pseudintermedius (26916); c Methicillin resistant Staphylococcus pseudintermedius, (C22963); d Staphylococcus aureus (ATCC 29213); e Pseudomonas aeruginosa (ATCC 27853); f Percentage of hemolysis at 150 µM.
Effect of single substitutions in position 5 on antibacterial (MIC, µg/mL) and hemolytic activity (% at 150 µM) of D2.
| ID | SEQUENCE a | MIC | HA f | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MSSP b | MRSP c | SA d | PA e | ||||||||||
|
| Nlys | Nlys | N1Nal | N4MePhe | Nlys | N1Nal | Nlys | NNle | 2–4 | 4 | 8 | 16 | 24 |
|
| NMe | 4 | 4 | 16 | 32 | 16 | |||||||
|
| N4MePhe | 8 | 8 | 8 | 16 | 69 | |||||||
|
| N1Nal | 8 | 8 | 8 | 16 | 87 | |||||||
|
| NEtOH | 8 | 8 | 32 | >64 | 5 | |||||||
a Products synthesized as C-terminal amides; b Methicillin sensitive Staphylococcus pseudintermedius (26916); c Methicillin resistant Staphylococcus pseudintermedius, (C22963); d Staphylococcus aureus (ATCC 29213); e Pseudomonas aeruginosa (ATCC 27853); f Percentage of hemolysis at 150 µM.
Structures, antimicrobial (MIC, µg/mL), and hemolytic activity (% at 150 µM) of l- (D2L), d- (D2D), retro- (D2R), and peptide–peptoid hybrid analogues (13–16) of D2.
| ID | SEQUENCE a | MIC | HA f | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MSSP b | MRSP c | SA d | PA e | ||||||||||
|
| Nlys | Nlys | N1Nal | N4MePhe | Nlys | N1Nal | Nlys | NNle | 2–4 | 4 | 8 | 16 | 24 |
|
| Lys | Lys | 1Nal | Phe | Lys | 1Nal | Lys | Nle | 16 | 8 | 32 | 16 | 35 |
|
| lys | lys | 1nal | phe | lys | 1nal | lys | nle | 1–4 | 4 | 4 | 4 | 35 |
|
| Nle | Lys | 1Nal | Lys | Phe | 1Nal | Lys | Lys | 16 | 4 | 32 | 32–64 | 23 |
|
| Nlys | Nlys | N1Nal | N4MePhe | lys | 1nal | lys | nle | 4 | 4 | 8 | 8 | 34 |
|
| lys | lys | 1nal | phe | Nlys | N1Nal | Nlys | NNle | 4 | 4 | 16 | 64 | 5 |
|
| Nlys | Nlys | 1nal | phe | Nlys | 1nal | Nlys | nle | 4 | 4 | 32 | >64 | 6 |
|
| lys | lys | N1Nal | N4MePhe | lys | N1Nal | lys | NNle | 4 | 4 | 16 | 64 | 4 |
a Products synthesized as C-terminal amides; b Methicillin sensitive Staphylococcus pseudintermedius (26916); c Methicillin resistant Staphylococcus pseudintermedius, (C22963); d Staphylococcus aureus (ATCC 29213); e Pseudomonas aeruginosa (ATCC 27853); f Percentage of hemolysis at 150 µM.
Figure 3Time–kill curves of D2D, the best candidate analogue identified in this study, against a clinical MRSP isolate (C22963). GC: growth control. We observed regrowth after 24 h (data not shown).
Spectrum of antimicrobial activity of D2 and D2D against a broad range of canine isolates, including Gram-positive and Gram-negative species.
| Bacteria | D2 | D2D |
|---|---|---|
| >64 | 16 | |
| 2 | 2 | |
| 64 | 4 | |
| >64 | 8 | |
| 16 | 4 | |
| >64 | 8 | |
| >64 | >64 | |
| 32 | 8 |
Figure 4Effect on membrane depolarization at sub-MIC concentrations (0.5× MIC) of the positive control CCCP, D2, D2D, D2L, D2R, and the negative control nisin. (A) Intensity of fluorescence (arbitrary units) is reported as function of the time; (B) change of fluorescence after 1.6 min for each compound ± SEM (n = 2).
Figure 5Effect of sub-MIC concentration of AMPs on macromolecule biosynthesis. (A) Effect on DNA and (B) cell wall synthesis in cells treated with sub-MIC concentrations (0.5× MIC) of D2D, D2L, and D2R after 20 min of incubation. The peptide nisin was used as control. Data are represented as means of two repeated experiments ± SEM.